Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients

[1]  H. Brauch,et al.  Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer , 2014, The Pharmacogenomics Journal.

[2]  I. Smith,et al.  Endocrine therapy for advanced/metastatic breast cancer. , 2013, Hematology/oncology clinics of North America.

[3]  R. Kim,et al.  CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy , 2013, Breast Cancer Research and Treatment.

[4]  H. Gurney,et al.  Evidence for therapeutic drug monitoring of targeted anticancer therapies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Jager,et al.  Effects of CYP Induction by Rifampicin on Tamoxifen Exposure , 2012, Clinical pharmacology and therapeutics.

[6]  J. Cuzick,et al.  CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. , 2012, Journal of the National Cancer Institute.

[7]  E. Ziv,et al.  Clinical and biomarker predictors of side effects from tamoxifen , 2012, Breast Cancer Research and Treatment.

[8]  E. Wiemer,et al.  Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. , 2011, Journal of pharmaceutical and biomedical analysis.

[9]  S. Ohdo,et al.  Molecular basis of chronopharmaceutics. , 2011, Journal of pharmaceutical sciences.

[10]  T. Fehm,et al.  Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma , 2011, Clinical pharmacology and therapeutics.

[11]  L. Natarajan,et al.  Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes , 2011, Clinical pharmacology and therapeutics.

[12]  K. Lunetta,et al.  CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. , 2011, Journal of the National Cancer Institute.

[13]  J. Baggs,et al.  The role of clock genes in pharmacology. , 2010, Annual review of pharmacology and toxicology.

[14]  M. Beckmann,et al.  Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. , 2009, JAMA.

[15]  L. Carey,et al.  CYP2D6 and tamoxifen: DNA matters in breast cancer , 2009, Nature Reviews Cancer.

[16]  R. Epstein,et al.  Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Klaassen,et al.  Circadian Expression Profiles of Drug-Processing Genes and Transcription Factors in Mouse Liver , 2009, Drug Metabolism and Disposition.

[18]  M. Baraldo.  The influence of circadian rhythms on the kinetics of drugs in humans , 2008, Expert opinion on drug metabolism & toxicology.

[19]  S. Amin,et al.  Elimination of Antiestrogenic Effects of Active Tamoxifen Metabolites by Glucuronidation , 2007, Drug Metabolism and Disposition.

[20]  Zeruesenay Desta,et al.  Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment , 2006, Clinical pharmacology and therapeutics.

[21]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[22]  Brahma N. Singh,et al.  Effects of Food on the Clinical Pharmacokinetics of Anticancer Agents , 2004, Clinical pharmacokinetics.

[23]  Zeruesenay Desta,et al.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.

[24]  J. Azuma,et al.  Circadian variation of the urinary 6β-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity , 2000, European Journal of Clinical Pharmacology.

[25]  B. Lemmer,et al.  Circadian changes in estimated hepatic blood flow in healthy subjects. , 1991, British journal of clinical pharmacology.

[26]  S. Lundgren,et al.  Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. , 1989, Cancer research.

[27]  J. Moore,et al.  Circadian variation in gastric emptying of meals in humans. , 1987, Gastroenterology.

[28]  D. Wingate,et al.  Circadian variation in the propagation velocity of the migrating motor complex. , 1986, Gastroenterology.

[29]  J. Moore,et al.  Circadian Rhythm of Gastric Acid Secretion in Man , 1970, Nature.